X4 Pharmaceuticals secures up to $150 million senior secured loan from K2 HealthVentures
X4 Pharmaceuticals entered a senior secured term loan facility with K2 HealthVentures for up to $150 million. An initial tranche of $80 million was funded at closing and used to repay $75 million of existing principal and related fees. The agreement provides a 48‑month maturity, a longer interest‑only period and the option to draw an additional $70 million subject to lender approval. The company says the financing will support corporate activities and the anticipated Phase 3 4WARD trial enrollment completion by year‑end 2026 and topline data in the first half of 2028.
Why it matters
The new facility improves X4’s cash position and extends its financing runway, giving the company flexibility to fund its Phase 3 trial and a potential commercial launch of mavorixafor for chronic neutropenia (the company says this supports its strategic priorities).
Key facts
- 1The loan facility size is up to $150 million. globenewswire.com
- 2The first tranche of $80 million was funded at closing. globenewswire.com
- 3$80 million was used to repay $75 million of principal and related fees under the prior loan. globenewswire.com
- 4An additional $70 million may be made available upon request, subject to K2 HealthVentures approval and other conditions. globenewswire.com
- 5The loan has a 48‑month maturity and a longer interest‑only period. globenewswire.com
- 6X4 expects to complete enrollment in the Phase 3 4WARD trial by the end of 2026 and receive topline results in the first half of 2028. globenewswire.com
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.